Literature DB >> 15172885

Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats.

Ning Liu1, Toshiaki Makino, Fumiaki Nogaki, Hitoshi Kusano, Katsuo Suyama, Eri Muso, Gisho Honda, Toru Kita, Takahiko Ono.   

Abstract

It is well known that tissue factor starts the extrinsic coagulation pathway, which activates factor X to Xa, and factor V is a membrane-bound potent cofactor for the terminating stage of prothrombin activation by factor Xa. In a previous in vitro study, factor V was induced in cultured mesangial cells by inflammatory stimulation and increased expression of factor V promoted fibrin generation on the cultured mesangial cell surface. We report that extracellular matrix (ECM) accumulation is increased in association with coagulation in the mesangial area through factor V expression in mesangioproliferative glomerulonephritis (MsPGN). Wistar rats were intravenously injected with rabbit anti-rat thymocyte serum accompanied with or without simultaneous injection of rabbit anti-factor V antibody. Time course study in immunohistochemistry revealed that factor V expression was prominent on day 3 and fibrin-related antigen (FRA) deposition, then ECM accumulation, followed from day 3 to day 8. Massive fibronectin depositions and transforming growth factor (TGF)-beta expression were also noted in glomeruli from the disease control group, markedly higher than those in the normal group, and these depositions and expressions were significantly decreased in the anti-factor V neutralizing antibody-injected group. Northern blot analysis revealed that factor V mRNA expression was prominent on day 3 and was weak on day 8. Double-labeling experiments revealed the frequent colocalization of alpha-smooth muscle actin with factor V, FRA, and fibronectin in the same mesangial areas of glomeruli. TGF-beta, connective tissue growth factor (CTGF), collagen type IV, and fibronectin mRNA were upregulated in the disease control group, and anti-factor V-neutralizing antibody injection suppressed these mRNA expressions in glomeruli. The present results suggest that ECM components accumulation may progress in accordance with coagulation in the mesangial area through mesangial factor V expression and upregulated expression of TGF-beta and CTGF in MsPGN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172885     DOI: 10.1152/ajprenal.00322.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

1.  Models of chronic kidney disease.

Authors:  Hai-Chun Yang; Yiqin Zuo; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2010

2.  Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet.

Authors:  F Li; C-H Wang; J-G Wang; T Thai; G Boysen; L Xu; A L Turner; A S Wolberg; N Mackman; N Maeda; N Takahashi
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

Review 3.  Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models.

Authors:  Omid Sadeghi-Alavijeh; Mohammad Tadayyon; Ben Caplin
Journal:  Cardiovasc Endocrinol       Date:  2017-11-15

4.  Soluble fibrin formation in the mesangial area of IgA nephropathy.

Authors:  Ning Liu; Noriko Mori; Noriyuki Iehara; Kazuhide Uemura; Atsushi Fukastu; Toru Kita; Michio Matsuda; Takahiko Ono
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

5.  Thrombin-induced VEGF expression in human retinal pigment epithelial cells.

Authors:  Zong-Mei Bian; Susan G Elner; Victor M Elner
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

6.  Association of human leukocyte antigen gene polymorphism and mesangial proliferative glomerulonephritis in a large population-based study.

Authors:  Jing-Jie Zhao; Xi-Bing Wang; Yun Luan; Jun-Li Liu; Ling Liu; Hong-Ying Jia
Journal:  Biomed Rep       Date:  2013-07-22

7.  The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study.

Authors:  Pawan Vasudeva; Dharamveer Singh; Apul Goel
Journal:  Indian J Urol       Date:  2008-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.